- HOME
- Products & Services
- Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business
-
Oligonucleotide API CDMO
-
Custom DNA/RNA Systhesis
-
Next Generation Sequencing
- Next Generation Sequencing
-
Application Selection Guide
- Application Selection Guide
- Human Genome Sequencing
- Whole Genome Sequencing (Non-Human)
- Microbial genome sequencing
- Small scale sequencing (NGS Petit)
- GRAS-Di® Genotyping
- Repeat Motif Detection
- Library Prep for Challenging DNA Samples
- Gene Expression Analysis (Reference-Based)
- Isoform Sequencing (full-length mRNA-seq)
- De novo Transcriptome Sequencing
- Small RNA-Seq
- Microbial Community Analysis
- Shotgun Metagenomic Sequencing
- Metatranscriptome Sequencing
- ChIP-Seq
- CRISPR Screening
- Illumina Amplicon Sequencing
- PacBio Amplicon Sequencing
- Standard Pipeline Data Analysis
- Custom Data Analysis
- Gene Analysis from Pathological Specimens
- Sequencer Models and Sequencing Principles
- Sample Requirements
- How to Order
- Scientific Publications
-
Custom DNA Sequencing
-
Custom DNA Microarray
-
Protein Related Service
-
Laboratory Tools and Service
- Nucleic Acid Extraction
- RNA Purification
- RNA Quality Control
- Custom Measurement for synthetic DNA Molecular Weight
- Full-length cDNA library Production Service
- Stock Series
- LaboPass™ Products Series
- Koro Koro Rack
- Ukkie
- 8-tube strip
- Rhodococcus erythropolis Protein Expression System
- LipoTrust™ Series
Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business
| Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business July 12th, 2024 We are pleased to announce that Hokkaido System Science Co., Ltd. (HSS), having a headquarters in Sapporo, Hokkaido (CEO: Yukio Mizutani) has signed a business collaboration agreement with Mitsubishi Gas Chemical Company, Inc. (MGC), having a headquarters in Chiyoda-ku, Tokyo (President: Masashi Fujii) to jointly explore entry into nucleic acid drug CDMO (Contract Development and Manufacturing Organization) business. HSS has engaged in synthesis and sales of nucleic acids for research use for more than 30 years. Based on such accumulated know-how about nucleic acid synthesis, and together with MGC’s analytical technology and knowledge of Good Manufacturing Practice (GMP), we will aim to launch a nucleic acid drug CDMO business to provide solutions for stakeholders including academic researchers.
|
|
| Download the PDF file. | |